2016-002811-16) is currently evaluating the administration of nivolumab (an anti-PD1 monoclonal antibody) for the palliative treatment of DEB patients with locally advanced or metastatic cSCC, unresponsive to other systemic therapies [40], although a few studies have reported that PD-L1 expression is predictive of clinical outcome in cSCC, so further investigations are still necessary [42,43]. Here, CD274 is linked to skin squamous cell carcinoma.